![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Based on Phase 3 trial data, Rizmoic has been shown to increase the frequency of bowel movements compared to placebo in patients either with cancer or chronic non-cancer pain who had previously received laxative treatment.
Lead Product(s): Naldemedine Tosylate
Therapeutic Area: Gastroenterology Product Name: Rizmoic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Shionogi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020